July 23, 2024
Approach for Male Contraception

A Groundbreaking Discovery: Non-Hormonal Sperm-Specific Approach for Male Contraception

The global population has witnessed a significant surge, growing from 3 billion in the late 1960s to an estimated 8 billion in 2022, with projections indicating a further increase to 9 billion by 2037. This population growth highlights the importance of family planning, yet advancements in contraception have been limited, particularly for men. Currently, there is no oral contraceptive pill available for men.

Researchers at Baylor College of Medicine and collaborating institutions have made a promising breakthrough in this area. In a recent study published in the journal Science, they demonstrated the potential of a novel, non-hormonal approach for reversible human male contraception using animal models.

Dr. Martin Matzuk, the study’s corresponding author, director of the Center for Drug Discovery, and chair of the Department of Pathology and Immunology at Baylor, explained, “Despite ongoing research efforts, we still lack a birth control pill for men.”

The researchers focused on a novel strategy: identifying a small molecule that could inhibit serine/threonine kinase 33 (STK33), a protein essential for fertility in both men and mice. Previous research has shown that STK33 is predominantly found in the testis and plays a crucial role in the formation of functional sperm. In mice, the absence of the Stk33 gene results in sterility due to abnormal sperm and poor motility. In men, a mutation in the STK33 gene leads to infertility caused by similar sperm defects. Remarkably, these individuals exhibit no other health issues and have normal testis size.

STK33 is considered an attractive target for male contraception due to its minimal safety concerns. Although STK33 inhibitors have been identified, none have been shown to specifically and potently disrupt STK33 function in living organisms.

Dr. Matzuk, who has been a faculty member at Baylor for 30 years and holds the Stuart A. Wallace Chair and Robert L. Moody, Sr. Chair of Pathology and Immunology, stated, “STK33 is a promising target for male contraception with minimal safety concerns.” This groundbreaking discovery brings us one step closer to developing a safe and effective birth control pill for men.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it.